Implementation of the new version of the medical insurance catalogue, 119 national talks officially reduced the price of drugs

Medical Network News on March 2　

 

Implementation of the new version of the medical insurance catalogue, 119 exclusive products are greatly reduced

 

On March 1, the 2020 version of the National Medical Insurance Catalogue was officially implemented.
At the same time, the price of drugs negotiated by the state also officially took effect (see the end of the text for the detailed form).

 

From the perspective of negotiated varieties, there were 119 successful negotiations in 2020, of which 96 were successfully negotiated outside the catalog and 23 were successfully negotiated in the catalog.
The average price of successfully negotiated drugs was reduced by 50.
64%, and the price of individual anticancer drugs was even as high as 80%.

 

What everyone is most concerned about should be the negotiated product prices that companies apply for confidentiality in the new version of the medical insurance catalog.
It is understood that the price cuts of some varieties are indeed very large, some of which are as follows:

 

Treprizumab:

 

For example, on February 23, the Jilin Provincial Public Resources Trading Center announced the "Results of Online Procurement of Varieties in Price Negotiations during the 2021 Agreement", which showed that the price of Junshi Bio's "Treprizumab" 240mg was 2,100.
97 yuan per tube.
.

 

Teriplizumab was approved in China on December 17, 2018.
It is the first domestically produced anti-PD-1 mAb to be marketed in China.
Its first approved indication is for unresectable failures in previous systemic treatments.
Or the treatment of metastatic melanoma, this is also the indication for the medical insurance.
According to the State Food and Drug Administration, on February 19, it was approved for new indications for recurrent/metastatic nasopharyngeal cancer patients who had previously failed second-line and above systemic treatments.

 

　　Before the medical insurance negotiations, the price of 240mg of teriprizumab was 7,200 yuan per tube.
Now the negotiated price of medical insurance has dropped to 2,100.
97 yuan, a drop of 71%.
Even if you count the four-time gift-giving program, it costs 3,600 yuan per unit, and the actual expenditure of the patient is directly reduced by 42%, which reduces a large part of the burden for the patient.

 

　　Tilelizumab:

 

　　For example, BeiGene's star product tislelizumab (BaiZian), the indication for entering the medical insurance this time is the treatment of relapsed or refractory classic Hodgkin's lymphoma after at least second-line chemotherapy; PD- The failure of platinum-containing chemotherapy with high L1 expression includes the treatment of locally advanced or metastatic urothelial carcinoma that has progressed within 12 months of neoadjuvant or adjuvant chemotherapy.
It is understood that the original price is 10688 yuan/100mg, and the negotiated price of medical insurance is 2180 yuan/100mg, which is a price drop of nearly 80%.
Even if the original drug donation policy "3+x or 2+2 cycle after 2+2" is counted, the price reduction this time is still very large.

 

　　Lenvatinib:

 

　　For example, lenvatinib (Levima), which is used in patients with unresectable hepatocellular carcinoma who have not received systemic treatment in the past, is also the indication for this entry into the medical insurance list.
According to an informed source, it was used before the national medical insurance negotiations.
The price is 3240 yuan/box, and the price has dropped by more than 80% after national negotiations.

 

　　7 more rare disease drugs are included in medical insurance

 

　　In fact, the day before the full implementation of the new medical insurance catalog on March 1, that is, February 28, is International Rare Disease Day.
It is understood that 7 new rare disease treatment drugs have been included this time.
This is a great boon for patients with rare diseases and their families.

 

　　Rare disease treatment drugs newly included in medical insurance:

 

　　There are more than 7,000 rare diseases, 80% of which are genetic diseases, 60-70% of them develop in childhood, and most of the rare diseases are severely fatal or disabling.
Because they are rare, the public and doctors have insufficient understanding of the disease, and it is easy to delay diagnosis and treatment or misdiagnosis and treatment.
.
At the same time, because there are few patients for each rare disease and the relatively high cost of treatment research and development, many pharmaceutical companies are not motivated to actively produce rare disease drugs, including cheap drugs and expensive drugs.
Drugs for rare diseases are also commonly known as "orphan drugs.
"

 

　　In recent years, it has become the consensus of the industry and the whole society to overcome the difficult problems of rare disease diagnosis and treatment and medication protection.
On February 27, the Rare Disease Expert Committee of the Guangdong Pharmaceutical Association was formally established in Guangzhou, dedicated to helping and caring for more rare disease patients.

 

　　At the meeting, Professor Liu Li, chief physician of the Department of Genetics and Endocrinology of Guangzhou Women’s and Children’s Medical Center, pointed out that the diagnosis, treatment and medication of rare diseases covers multiple links such as hospitals , pharmaceutical companies, distribution companies, and DTP pharmacies.
It is a very collaborative industry requirement.
High field.

 

　　Judging from the results of this national drug price negotiation, more and more rare disease drugs have entered the medical insurance list, the payment pressure of some rare disease patients has begun to decline, and the availability of rare disease drugs has greatly improved.
At the same time, the participation of pharmaceutical manufacturers and pharmaceutical distribution companies has opened up information exchange channels with hospitals.
On the one hand, it can effectively stimulate the enthusiasm of pharmaceutical companies to develop and produce drugs for rare diseases.
On the other hand, retail pharmacies as drug distribution terminals have also opened up.
more choices.

 

　　It is understood that as of now, 55 drugs have been included in the National Medical Insurance List among the diseases included in the National Rare Disease List for the treatment of 24 rare disease indications.

 

　　Under the general trend of prescription outflow, pharmaceutical distribution companies have taken advantage of the wholesale and retail linkages to set up professional prescription dispensing pharmacies, seamlessly connect with medical institutions, and improve the availability of medications for patients, including drugs for rare diseases.
Taking the representatives of participating circulation companies and DTP pharmacy Guangzhou Pharmaceutical Pharmacy as an example, they can give full play to the advantages of professional services for patients in supporting rare diseases, and better achieve the "three-medicine linkage" fight with medical institutions, medical insurance institutions and pharmaceutical companies.
Cooperate.
With the continuous improvement of national medical insurance, regional medical insurance "dual channels" and urban commercial medical insurance, the burden of payment for medication has been greatly reduced.

 

　　Medical insurance negotiations, the driving force for pharmaceutical companies to innovate

 

　　In recent years, the structural adjustment of the medical insurance catalogue has shown a clear trend.
The payment of medical insurance is tilted towards more drugs for tumors, rare diseases and chronic diseases.
The results of this medical insurance negotiation also reflect this characteristic.

 

　　Medical insurance negotiations are the driving force behind corporate innovation, not only determining the development prospects of innovative drugs , but also an important catalyst for the increase in volume of innovative drugs.
In recent years, many drugs have been negotiated to be included in the medical insurance, not only have been rapidly increased, but also the sales have skyrocketed.

 

　　According to the analysis of Industrial Securities, from the perspective of the products successfully negotiated in the previous medical insurance negotiations, the products with better competition pattern and the products with relatively fierce competition can achieve faster volume after being included in the medical insurance through negotiation, bringing flexibility to the corresponding products.

 

　　The varieties with a better competitive landscape take trastuzumab and osimertinib as examples.
They both achieved rapid volume after being included in medical insurance through negotiation, which greatly reflects that the inclusion of medical insurance can help accelerate the growth of innovative drugs.
Before being included in medical insurance, although these drugs had high clinical value, their relatively high prices resulted in low market penetration.
After entering the medical insurance, the clinical use rate of these drugs has increased rapidly.

 

　　The relatively fierce competition pattern takes the ALK inhibitor as an example.
On the one hand, its mutation rate is relatively low.
On the other hand, in the 2018 negotiation catalog, the first-generation crizotinib and the second-generation ceritinib were included in the negotiation catalog at the same time.
.
As a result, both varieties achieved accelerated volume after being included.

 

 

　　At present, my country's medical insurance negotiation system has gradually improved, and it has gradually become the norm for innovative drugs to be included in the medical insurance negotiation catalog at a substantial price reduction in the initial stage of the market.
At the same time, the state has introduced a series of innovation benefits, such as accelerating the review and approval of innovative drugs, and patent extension policies to fully support the development of innovative drugs.
Innovation has become an unstoppable industry trend.

 

　　Attached:

 

　　Negotiated drugs during the agreement period (Western medicine)

 

　　Negotiated drugs during the agreement period (Chinese patent medicine)

Medical Network News on March 2　

 

　　Implementation of the new version of the medical insurance catalogue, 119 exclusive products are greatly reduced

 

　　On March 1, the 2020 version of the National Medical Insurance Catalogue was officially implemented.
At the same time, the price of drugs negotiated by the state also officially took effect (see the end of the text for the detailed form).

 

　　From the perspective of negotiated varieties, there were 119 successful negotiations in 2020, of which 96 were successfully negotiated outside the catalog and 23 were successfully negotiated in the catalog.
The average price of successfully negotiated drugs was reduced by 50.
64%, and the price of individual anticancer drugs was even as high as 80%.

 

　　What everyone is most concerned about should be the negotiated product prices that companies apply for confidentiality in the new version of the medical insurance catalog.
It is understood that the price cuts of some varieties are indeed very large, some of which are as follows:

 

　　Treprizumab:

 

　　For example, on February 23, the Jilin Provincial Public Resources Trading Center announced the "Results of Online Procurement of Varieties in Price Negotiations during the 2021 Agreement", which showed that the price of Junshi Bio's "Treprizumab" 240mg was 2,100.
97 yuan per tube.
.

 

　　Teriplizumab was approved in China on December 17, 2018.
It is the first domestically produced anti-PD-1 mAb to be marketed in China.
Its first approved indication is for unresectable failures in previous systemic treatments.
Or the treatment of metastatic melanoma, this is also the indication for the medical insurance.
According to the State Food and Drug Administration, on February 19, it was approved for new indications for recurrent/metastatic nasopharyngeal cancer patients who had previously failed second-line and above systemic treatments.

 

　　Before the medical insurance negotiations, the price of 240mg of teriprizumab was 7,200 yuan per tube.
Now the negotiated price of medical insurance has dropped to 2,100.
97 yuan, a drop of 71%.
Even if you count the four-time gift-giving program, it costs 3,600 yuan per unit, and the actual expenditure of the patient is directly reduced by 42%, which reduces a large part of the burden for the patient.

 

　　Tilelizumab:

 

　　For example, BeiGene's star product tislelizumab (BaiZian), the indication for entering the medical insurance this time is the treatment of relapsed or refractory classic Hodgkin's lymphoma after at least second-line chemotherapy; PD- The failure of platinum-containing chemotherapy with high L1 expression includes the treatment of locally advanced or metastatic urothelial carcinoma that has progressed within 12 months of neoadjuvant or adjuvant chemotherapy.
It is understood that the original price is 10688 yuan/100mg, and the negotiated price of medical insurance is 2180 yuan/100mg, which is a price drop of nearly 80%.
Even if the original drug donation policy "3+x or 2+2 cycle after 2+2" is counted, the price reduction this time is still very large.

 

　　Lenvatinib:

 

　　For example, lenvatinib (Levima), which is used in patients with unresectable hepatocellular carcinoma who have not received systemic treatment in the past, is also the indication for this entry into the medical insurance list.
According to an informed source, it was used before the national medical insurance negotiations.
The price is 3240 yuan/box, and the price has dropped by more than 80% after national negotiations.

 

　　7 more rare disease drugs are included in medical insurance

 

　　In fact, the day before the full implementation of the new medical insurance catalog on March 1, that is, February 28, is International Rare Disease Day.
It is understood that 7 new rare disease treatment drugs have been included this time.
This is a great boon for patients with rare diseases and their families.

 

　　Rare disease treatment drugs newly included in medical insurance:

 

　　There are more than 7,000 rare diseases, 80% of which are genetic diseases, 60-70% of them develop in childhood, and most of the rare diseases are severely fatal or disabling.
Because they are rare, the public and doctors have insufficient understanding of the disease, and it is easy to delay diagnosis and treatment or misdiagnosis and treatment.
.
At the same time, because there are few patients for each rare disease and the relatively high cost of treatment research and development, many pharmaceutical companies are not motivated to actively produce rare disease drugs, including cheap drugs and expensive drugs.
Drugs for rare diseases are also commonly known as "orphan drugs.
"

 

　　In recent years, it has become the consensus of the industry and the whole society to overcome the difficult problems of rare disease diagnosis and treatment and medication protection.
On February 27, the Rare Disease Expert Committee of the Guangdong Pharmaceutical Association was formally established in Guangzhou, dedicated to helping and caring for more rare disease patients.

 

　　At the meeting, Professor Liu Li, chief physician of the Department of Genetics and Endocrinology of Guangzhou Women’s and Children’s Medical Center, pointed out that the diagnosis, treatment and medication of rare diseases covers multiple links such as hospitals , pharmaceutical companies, distribution companies, and DTP pharmacies.
It is a very collaborative industry requirement.
High field.

 

　　Judging from the results of this national drug price negotiation, more and more rare disease drugs have entered the medical insurance list, the payment pressure of some rare disease patients has begun to decline, and the availability of rare disease drugs has greatly improved.
At the same time, the participation of pharmaceutical manufacturers and pharmaceutical distribution companies has opened up information exchange channels with hospitals.
On the one hand, it can effectively stimulate the enthusiasm of pharmaceutical companies to develop and produce drugs for rare diseases.
On the other hand, retail pharmacies as drug distribution terminals have also opened up.
more choices.

 

　　It is understood that as of now, 55 drugs have been included in the National Medical Insurance List among the diseases included in the National Rare Disease List for the treatment of 24 rare disease indications.

 

　　Under the general trend of prescription outflow, pharmaceutical distribution companies have taken advantage of the wholesale and retail linkages to set up professional prescription dispensing pharmacies, seamlessly connect with medical institutions, and improve the availability of medications for patients, including drugs for rare diseases.
Taking the representatives of participating circulation companies and DTP pharmacy Guangzhou Pharmaceutical Pharmacy as an example, they can give full play to the advantages of professional services for patients in supporting rare diseases, and better achieve the "three-medicine linkage" fight with medical institutions, medical insurance institutions and pharmaceutical companies.
Cooperate.
With the continuous improvement of national medical insurance, regional medical insurance "dual channels" and urban commercial medical insurance, the burden of payment for medication has been greatly reduced.

 

　　Medical insurance negotiations, the driving force for pharmaceutical companies to innovate

 

　　In recent years, the structural adjustment of the medical insurance catalogue has shown a clear trend.
The payment of medical insurance is tilted towards more drugs for tumors, rare diseases and chronic diseases.
The results of this medical insurance negotiation also reflect this characteristic.

 

　　Medical insurance negotiations are the driving force behind corporate innovation, not only determining the development prospects of innovative drugs , but also an important catalyst for the increase in volume of innovative drugs.
In recent years, many drugs have been negotiated to be included in the medical insurance, not only have been rapidly increased, but also the sales have skyrocketed.

 

　　According to the analysis of Industrial Securities, from the perspective of the products successfully negotiated in the previous medical insurance negotiations, the products with better competition pattern and the products with relatively fierce competition can achieve faster volume after being included in the medical insurance through negotiation, bringing flexibility to the corresponding products.

 

　　The varieties with a better competitive landscape take trastuzumab and osimertinib as examples.
They both achieved rapid volume after being included in medical insurance through negotiation, which greatly reflects that the inclusion of medical insurance can help accelerate the growth of innovative drugs.
Before being included in medical insurance, although these drugs had high clinical value, their relatively high prices resulted in low market penetration.
After entering the medical insurance, the clinical use rate of these drugs has increased rapidly.

 

　　The relatively fierce competition pattern takes the ALK inhibitor as an example.
On the one hand, its mutation rate is relatively low.
On the other hand, in the 2018 negotiation catalog, the first-generation crizotinib and the second-generation ceritinib were included in the negotiation catalog at the same time.
.
As a result, both varieties achieved accelerated volume after being included.

 

 

　　At present, my country's medical insurance negotiation system has gradually improved, and it has gradually become the norm for innovative drugs to be included in the medical insurance negotiation catalog at a substantial price reduction in the initial stage of the market.
At the same time, the state has introduced a series of innovation benefits, such as accelerating the review and approval of innovative drugs, and patent extension policies to fully support the development of innovative drugs.
Innovation has become an unstoppable industry trend.

 

　　Attached:

 

　　Negotiated drugs during the agreement period (Western medicine)

 

　　Negotiated drugs during the agreement period (Chinese patent medicine)